法国研究:结外NK/T细胞淋巴瘤鼻型患者造血干细胞移植的结局
该法国多中心回顾性研究评估了65例接受造血干细胞移植(HSCT)的结外NK/T细胞淋巴瘤鼻型(ENKTL)患者,其中19例异基因、46例自体移植。中位随访79.9个月,4年无进展生存(PFS)和总生存(OS)在两组间相似。移植时缓解状态是生存的独立预后因素。与仅接受化疗和/或放疗的对照相比, upfront HSCT未改善应答者结局,但可能为复发且获二次缓解的高危患者带来生存获益。
要点
- 移植时缓解状态是ENKTL患者HSCT后生存的主要独立预后因素。
- 自体与异基因HSCT的4年PFS和OS无显著差异。
- upfront HSCT未改善应答者结局,但可能使复发后二次缓解的高危患者获益。
核心结论
- HSCT应被考虑用于选定复发ENKTL患者的巩固治疗,而upfront治疗中的地位尚待明确。
研究设计与样本
- 法国SFGM-TC回顾性研究,纳入65例接受HSCT的ENKTL患者,其中19例异基因、46例自体移植。
主要发现
- 与仅接受化疗和/或放疗的对照相比,upfront HSCT未改善应答者(包括接受L-天冬酰胺酶者)的结局。
- upfront HSCT倾向于为复发且初始高危临床特征、获二次缓解的患者提供生存获益。
临床怎么用
- 对复发ENKTL且获二次缓解的选定患者,可考虑HSCT作为巩固治疗。
- 移植前应尽可能达到缓解,因移植时缓解状态是生存的独立预后因素。
局限性
- 回顾性研究设计,样本量有限(65例),非亚洲人群队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated the outcome of 65 French patients with Extranodal NK/T-cell lymphoma, nasal type (ENKTL) undergoing hematopoietic stem cell transplantation (HSCT) (19 allogeneic and 46 autologous). Fifty-four patients (83%), most of which receiving L-asparaginase (L-aspa) containing regimens (81%), achieved complete or partial response at time of HCST. After a median follow-up of 79.9 months, 4-years progression-free survival (PFS) and overall survival (OS) were similar in both autologous and allogeneic groups (PFS: 34% vs. 26%, p = .12 and OS: 52% vs. 53%, p = .74). Response status at HSCT was the major independent prognostic factor on survival (OS: HR: 4.013 [1.137; 14.16], p = .031 and PFS: HR: 5.231 [1.625; 16.838], p = .006). As compared to control patients receiving chemotherapy and/or radiotherapy containing regimens only, upfront HSCT did not improve the outcome of responder patients, including those treated by L-aspa. However, it tends to provide survival benefit for relapsed patients with initial high-risk clinical features who achieved second remission. Whereas the place of HSCT in upfront therapy has still to be clarified, these data confirm that HSCT should be considered for consolidation in selected patients with relapsed ENKTL. Based on a large non Asian ENKTL cohort since the L-aspa era, this study provides some insight into the survival patterns of ENKTL patients with HSCT in the Western hemisphere and may give future direction for the next clinical trial design.
引用
- Philippe Walter L, Couronné L, Jais JP, et al. Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Am J Hematol. 2021. PMID: 33864708. doi:10.1002/ajh.26200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。